Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | IDO1 | P14902 | 2/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | PDE2A | O00408 | 1/20 | 0.31 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.31 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11957475 | 0.83 | HDAC8 (0.34) | ACACBMAOAMAOBIDO1HDAC8 | |
| SCHEMBL15565140 | 0.80 | IDO1 (0.36) | ACACBMAOAMAOBIDO1HDAC8 | |
| SCHEMBL19440253 | 0.79 | ACACB (0.33) | ACACBMAOAMAOBIDO1HDAC8 | |
| SCHEMBL16070730 | 0.77 | POLB (0.33) | ACACBMAOAMAOBIDO1HDAC8 | |
| SCHEMBL16070675 | 0.77 | POLB (0.33) | ACACBMAOAMAOBIDO1HDAC8 | |
| SCHEMBL17518181 | 0.77 | POLB (0.33) | ACACBMAOAMAOBIDO1HDAC8 | |
| SCHEMBL683167 | 0.77 | AGXT (0.48) | MAOBIDO1 | |
| SCHEMBL683150 | 0.77 | TDP1 (0.37) | IDO1RCE1 | |
| SCHEMBL8968738 | 0.77 | TAAR1 (0.45) | IDO1 | |
| SCHEMBL12344408 | 0.77 | ACACB (0.41) | ACACBMAOBIDO1HDAC8PDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1268421-B1 | PHENYL-SUBSTITUTED INDOLES AS HISTAMINE H3-RECEPTOR ANTAGONISTS | ORTHO MCNEIL PHARM INC (US) | 2009-05-06 | — | — | EP | disclosed |
| US-6872834-B2 | Phenyl-substituted indoles and indazoles | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2005-03-29 | — | — | US | disclosed |
| EP-1268421-A2 | PHENYL-SUBSTITUTED INDOLES AS HISTAMINE H3-RECEPTOR ANTAGONISTS | Ortho-McNeil Pharmaceutical, Inc. (US) | 2003-01-02 | — | — | EP | disclosed |
| US-20020006928-A1 | Phenyl-substituted indoles and indazoles | ORTHO MCNEIL PHARMACEUTICAL, INC. | 2002-01-17 | — | — | US | disclosed |
| WO-2001074773-A2 | PHENYL-SUBSTITUTED INDOLES AS HISTAMINE H3-RECEPTOR ANTAGONISTS | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2001-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020006928-A1 | Phenyl-substituted indoles and indazoles | IDO1, IDO2, AADAC | ACACB 1896/4885MAOA 55/4885MAOB 71/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.